As on 04-Dec-2023 16:00 EST
$6.10
$6.03
$6.28
$5.74
473,760
$5.01 - 11.48
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
COMPASS Pathways (CMPS)
| -24.03 | -4.84 | -34.62 | -45.58 | -51.50 | -- | -- |
S&P BSE Sensex*
| 13.75 | 7.53 | 5.46 | 10.08 | 15.36 | 13.88 | 12.82 |
S&P BSE Healthcare#
| 32.48 | 9.92 | 9.75 | 27.53 | 13.31 | 16.60 | 12.24 |
2022
|
2021
|
|
---|---|---|
COMPASS Pathways (CMPS)
| -63.67 | -53.61 |
S&P BSE Sensex
| 4.44 | 21.99 |
S&P BSE Healthcare
| -12.10 | 20.87 |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
The total asset value of COMPASS Pathways Plc (CMPS) stood at $ 185 Mln as on 31-Mar-23
The share price of COMPASS Pathways Plc (CMPS) is $6.10 (NASDAQ) as of 04-Dec-2023 16:00 EST. COMPASS Pathways Plc (CMPS) has given a return of -51.5% in the last 3 years.
COMPASS Pathways Plc (CMPS) has a market capitalisation of $ 360 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of COMPASS Pathways Plc (CMPS) is 2.18 times as on 02-Jun-2023, a -0.18% premium to its peers’ median range of 2.67 times.
Since, TTM earnings of COMPASS Pathways Plc (CMPS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the COMPASS Pathways Plc (CMPS) and enter the required number of quantities and click on buy to purchase the shares of COMPASS Pathways Plc (CMPS).
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
The CEO & director of Mr. George Jay Goldsmith. is COMPASS Pathways Plc (CMPS), and CFO & Sr. VP is Dr. Ekaterina Malievskaia M.D..
The promoters of COMPASS Pathways Plc (CMPS) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
330
|
|
161
|
|
116
|
|
79
|
COMPASS Pathways Plc (CMPS) | Ratios |
---|---|
Return on equity(%)
|
-53.08
|
Return on capital employed(%)
|
--
|
Debt-to-equity ratio
|
0
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of COMPASS Pathways Plc (CMPS) was $-39 Mln.
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression;... and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. Read more
Sign up and get access to:
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.